Đang chuẩn bị liên kết để tải về tài liệu:
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). |

TÀI LIỆU LIÊN QUAN

Qualifying and quantifying the precision medicine rhetoric

GMIEC: A shiny application for the identification of gene-targeted drugs for precision medicine

Biomarkers: Paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma

From prospective biobanking to precision medicine: BIO-RAIDs – an EU study protocol in cervical cancer

Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine

Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: A theranostic study on response prediction of the key therapeutic agents

The use of PanDrugs to prioritize anticancer drug treatments in a case of TALL based on individual genomic data

Lung ultrasound in infants with bronchiolitis

Data and knowledge management in translational research: Implementation of the eTRIKS platform for the IMI OncoTrack consortium

My personal mutanome: A computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.